Trilaciclib in combination with immunotherapy plus chemotherapy as the first-line treatment for non-small cell lung cancer:a case-report and literature-review
According to the latest statistical data from the National Cancer Registry,lung cancer still ranks the first in morbidity and mortality among all kinds of malignancies in China.Both the morbidity and mortality of lung cancer are increasing year by year,causing a heavy burden to both society and families.Non-small cell lung cancer(NSCLC)remains the main pathological type of lung cancer,accounting for approximately 85％.To date,the 5-year survival rate of the patients with advanced NSCLC remains very low.Chemotherapy is still considered the cornerstone for the treatment of advanced NSCLC.Cytotoxic drugs can damage hematopoietic stem cells in the bone marrow,resulting in bone marrow suppression,and the patients have to stop the treatment due to intolerance.Traditional therapies for myelosuppression may cause other side effects,including depletion of bone marrow hematopoietic reserve.In July 2022,trilaciclib was approved by National Medical Products Administration(NMPA)for preventing bone marrow suppression in small-cell lung cancer.Previous studies showed that trilaciclib could effectively prevent bone marrow suppression without influencing anti-tumor efficacy.This case report aims to report a case of trilaciclib combined with immunotherapy plus chemotherapy for the prevention of myelosuppression in the first-line treatment of patients with advanced NSCLC,aiming to provide reference and basis for clinical practice.
NETL
NSTL
万方数据
